New advances in genomics and epigenetics in antiphospholipid syndrome.

"Disclosure statement : The authors have declared no conflicts of interest."

"Funding This study was supported by grants PI21/00591, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and RD21/0002/0033 Health Outcomes-Oriented Cooperative Research Networks, granted by the Instituto de Salud Carlos III (ISCIII) and funded by the European Union—NextGenerationEU via Mecanismo de Recuperación y Resiliencia and Plan de Recuperación, Transformación y Resiliencia. C.L.-P. was supported by a contract from the Spanish Junta de Andalucía (Nicolas Monardes program). T.C. was supported by the Sara Borrell program of the ISCIII (CD21/00187). L.M.B. was supported by a predoctoral grant from the ISCIII (FI22/00299). C.P.S. was financed by a contract from the MINECO Ramon y Cajal program (RYC2021-033828-I), cofounded by the European Union NextGenerationEU/PRTR. Disclosure statement: The authors have declared no conflicts of interest."